VJHemOnc Podcast iwAL 2019: looking to the future of acute leukemia therapy
Jun 6, 2019
Experts discuss advancements in acute leukemia therapy, including the use of measurable residual disease and CAR T-cell therapy. Challenges in immune therapies for acute myeloid leukemia are explored, along with the potential of small molecules and combination therapies. A study combining bortezumib and dixymethasone for acute leukemia therapy is examined, despite being halted due to increased toxicity. The difficulties of subgroup studies in acute myeloid leukemia are discussed, emphasizing the need for innovative approaches. A recent meeting on acute leukemia therapy is reflected upon, highlighting the importance of choosing relevant topics and positive interactions with pharmaceutical companies and colleagues.
Chapters
Transcript
Episode notes
1 2 3 4 5
Introduction
00:00 • 2min
Challenges and Progress in Immune Therapies for AML
01:39 • 21min
Combining Bortezumib and Dixymethasone for Acute Leukemia Therapy
22:56 • 2min
Challenges and Innovations in AML Subgroup Studies
24:47 • 5min
A Reflection on a Meeting on Acute Leukemia Therapy
29:42 • 2min